Cargando…
Retina stem cells, hopes and obstacles
Retinal degeneration is a major contributor to visual dysfunction worldwide. Although it comprises several eye diseases, loss of retinal pigment epithelial (RPE) and photoreceptor cells are the major contributors to their pathogenesis. Early therapies included diverse treatments, such as provision o...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Baishideng Publishing Group Inc
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8567457/ https://www.ncbi.nlm.nih.gov/pubmed/34786153 http://dx.doi.org/10.4252/wjsc.v13.i10.1446 |
_version_ | 1784594237088595968 |
---|---|
author | German, Olga L Vallese-Maurizi, Harmonie Soto, Tamara B Rotstein, Nora P Politi, Luis Enrique |
author_facet | German, Olga L Vallese-Maurizi, Harmonie Soto, Tamara B Rotstein, Nora P Politi, Luis Enrique |
author_sort | German, Olga L |
collection | PubMed |
description | Retinal degeneration is a major contributor to visual dysfunction worldwide. Although it comprises several eye diseases, loss of retinal pigment epithelial (RPE) and photoreceptor cells are the major contributors to their pathogenesis. Early therapies included diverse treatments, such as provision of anti-vascular endothelial growth factor and many survival and trophic factors that, in some cases, slow down the progression of the degeneration, but do not effectively prevent it. The finding of stem cells (SC) in the eye has led to the proposal of cell replacement strategies for retina degeneration. Therapies using different types of SC, such as retinal progenitor cells (RPCs), embryonic SC, pluripotent SCs (PSCs), induced PSCs (iPSCs), and mesenchymal stromal cells, capable of self-renewal and of differentiating into multiple cell types, have gained ample support. Numerous preclinical studies have assessed transplantation of SC in animal models, with encouraging results. The aim of this work is to revise the different preclinical and clinical approaches, analyzing the SC type used, their efficacy, safety, cell attachment and integration, absence of tumor formation and immunorejection, in order to establish which were the most relevant and successful. In addition, we examine the questions and concerns still open in the field. The data demonstrate the existence of two main approaches, aimed at replacing either RPE cells or photoreceptors. Emerging evidence suggests that RPCs and iPSC are the best candidates, presenting no ethical concerns and a low risk of immunorejection. Clinical trials have already supported the safety and efficacy of SC treatments. Serious concerns are pending, such as the risk of tumor formation, lack of attachment or integration of transplanted cells into host retinas, immunorejection, cell death, and also ethical. However, the amazing progress in the field in the last few years makes it possible to envisage safe and effective treatments to restore vision loss in a near future. |
format | Online Article Text |
id | pubmed-8567457 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Baishideng Publishing Group Inc |
record_format | MEDLINE/PubMed |
spelling | pubmed-85674572021-11-15 Retina stem cells, hopes and obstacles German, Olga L Vallese-Maurizi, Harmonie Soto, Tamara B Rotstein, Nora P Politi, Luis Enrique World J Stem Cells Review Retinal degeneration is a major contributor to visual dysfunction worldwide. Although it comprises several eye diseases, loss of retinal pigment epithelial (RPE) and photoreceptor cells are the major contributors to their pathogenesis. Early therapies included diverse treatments, such as provision of anti-vascular endothelial growth factor and many survival and trophic factors that, in some cases, slow down the progression of the degeneration, but do not effectively prevent it. The finding of stem cells (SC) in the eye has led to the proposal of cell replacement strategies for retina degeneration. Therapies using different types of SC, such as retinal progenitor cells (RPCs), embryonic SC, pluripotent SCs (PSCs), induced PSCs (iPSCs), and mesenchymal stromal cells, capable of self-renewal and of differentiating into multiple cell types, have gained ample support. Numerous preclinical studies have assessed transplantation of SC in animal models, with encouraging results. The aim of this work is to revise the different preclinical and clinical approaches, analyzing the SC type used, their efficacy, safety, cell attachment and integration, absence of tumor formation and immunorejection, in order to establish which were the most relevant and successful. In addition, we examine the questions and concerns still open in the field. The data demonstrate the existence of two main approaches, aimed at replacing either RPE cells or photoreceptors. Emerging evidence suggests that RPCs and iPSC are the best candidates, presenting no ethical concerns and a low risk of immunorejection. Clinical trials have already supported the safety and efficacy of SC treatments. Serious concerns are pending, such as the risk of tumor formation, lack of attachment or integration of transplanted cells into host retinas, immunorejection, cell death, and also ethical. However, the amazing progress in the field in the last few years makes it possible to envisage safe and effective treatments to restore vision loss in a near future. Baishideng Publishing Group Inc 2021-10-26 2021-10-26 /pmc/articles/PMC8567457/ /pubmed/34786153 http://dx.doi.org/10.4252/wjsc.v13.i10.1446 Text en ©The Author(s) 2021. Published by Baishideng Publishing Group Inc. All rights reserved. https://creativecommons.org/licenses/by-nc/4.0/This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/ |
spellingShingle | Review German, Olga L Vallese-Maurizi, Harmonie Soto, Tamara B Rotstein, Nora P Politi, Luis Enrique Retina stem cells, hopes and obstacles |
title | Retina stem cells, hopes and obstacles |
title_full | Retina stem cells, hopes and obstacles |
title_fullStr | Retina stem cells, hopes and obstacles |
title_full_unstemmed | Retina stem cells, hopes and obstacles |
title_short | Retina stem cells, hopes and obstacles |
title_sort | retina stem cells, hopes and obstacles |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8567457/ https://www.ncbi.nlm.nih.gov/pubmed/34786153 http://dx.doi.org/10.4252/wjsc.v13.i10.1446 |
work_keys_str_mv | AT germanolgal retinastemcellshopesandobstacles AT vallesemauriziharmonie retinastemcellshopesandobstacles AT sototamarab retinastemcellshopesandobstacles AT rotsteinnorap retinastemcellshopesandobstacles AT politiluisenrique retinastemcellshopesandobstacles |